Ur24Technology

Executive Summary

Ur24Technology has developed TrueClr™, the first non-invasive, non-adhesive external urinary catheter system that actively empties the bladder for men, women, and pediatrics. Unlike traditional indwelling catheters, TrueClr is leak-proof, portable, and easy to apply, eliminating common issues such as skin irritation, inflammation, and infections associated with adhesive-based external catheters or invasive Foley catheters. Headquartered in San Diego and founded in 2015, the company addresses a significant unmet need in urinary management, particularly for patients requiring long-term catheterization or those with mobility challenges. The product's design prioritizes patient comfort and dignity while reducing healthcare costs associated with catheter-related complications. Despite limited publicly available financial data, Ur24Technology's innovative approach positions it as a potential disruptor in the urology and continence care markets, which are traditionally dominated by invasive devices.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance or De Novo Classification for TrueClr70% success
• Q4 2026Commercial Partnership with Major Hospital Networks or Group Purchasing Organizations (GPOs)60% success
• Q2 2026Publication of Clinical Trial Results Demonstrating Superiority Over Standard Catheters75% success